The American pharmaceutical corporation Eli Lilly is in the final stages of negotiations to acquire the biotechnology company Kelonia Therapeutics. The deal is expected to exceed $2 billion, with an agreement potentially being reached very soon.
This is reported by Finway
Terms of the Deal and Strategic Importance
It is known that the final terms include the possibility of additional payments, which will depend on Kelonia Therapeutics achieving specific milestones in its research and development. So far, representatives from both companies have not provided official comments regarding the details of the negotiations.
Kelonia Therapeutics and the Prospects of CAR-T Therapy
Kelonia Therapeutics, based in Boston, specializes in creating innovative genetic therapies for the treatment of various diseases. The company’s primary focus is on developing CAR-T cell therapy, which involves modifying the patient’s immune cells to specifically target and destroy cancer cells. This approach opens new possibilities for combating oncological diseases.
The potential acquisition will strengthen Eli Lilly’s position in the oncology field. The company already has advanced therapies in its portfolio, including Jaypirca and Verzenio—a drug for the treatment of breast cancer. New investments will allow for an expanded presence in the dynamic and competitive oncology drug market.
In addition to its leadership in the development of obesity medications, Eli Lilly is actively diversifying its business by investing in treatments for inflammatory bowel diseases, ophthalmic conditions, and gene editing technologies. Earlier, in February 2026, the company announced its acquisition of Orna Therapeutics for up to $2.4 billion.
CAR-T therapy modifies the patient’s immune cells so they can recognize specific targets and destroy cancer cells.